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INTRODUCTION
While not unique to anti-microbial therapy, Clostridium difficile induced colitis is
most frequently encountered as a complication of treatment with one or more of
several antibiotics.1 4 The condition has been described in association with some
members of the cephalosporin group of drugs.5 Only on a few occasions has
cefotaxime been implicated in the past6.11 and, to date, no cases have been
reported in the United Kingdom. We describe a case in which a patient receiving
intramuscular cefotaxime developed a severe persistent diarrhoea which proved
to be the result of a C. difficile infection.
CASE REPORT
A 75-year-old man was admitted in March 1984 (day 1) with urinary retention
and increasing immobility. Four years previously he had been diagnosed as
having Parkinson's disease and there was a long history of prostatism
complicated by recurrent bladder outlet obstruction and urinary tract infections.
Apart from a degree of constipation during the months preceding admission, he
had had no other symptoms referrable to the gastrointestinal tract. He had no
known allergies and he had received amoxycillin and co-trimoxazole 6 months
earlier, without ill effect. His medication consisted of bromocriptine 2.5mg bd,
levodopa 200mg tid and carbidopa 50mg tid. Examination revealed a frail man
with signs of Parkinsonism and an abdomen unremarkable except for a tender
distended bladder. The rectum was empty and the urine, obtained by catheter-
isation, was cloudy. Culture of the urine yielded Proteus mirabilis and
Pseudomonas aeruginosa, both sensitive to cefotaxime. This antibiotic was
commenced at a dose of 1g bd, given intramuscularly, and no other antibiotics
were administered (day 6). On day 11, some faecal staining was noted on the
patient's clothing. The patient's urine became sterile and cefotaxime was
discontinued on day 14. In the following days the patient developed worsening
faecal incontinence and the stools became foul-smelling. Faecal cultures were
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negative for shigella, salmonella and camphylobacter species while no pathogens
were seen on microscopy. Codeine phosphate was commenced. On day 22, Ps.
aeruginosa, sensitive to cefotaxime, was again cultured from the patient's urine
so cefotaxime was recommenced using the same dose and route as previously.
By day 29 the urinary problems had cleared and the drug was again withdrawn.
The patient's diarrhoea continued to worsen, and microbiological stool analysis
still yielded no definite pathogens. On day 33, the patient became toxic with a
temperature of 39.2 0C and he sustained several rigors. Intramuscular cefotaxime
was again started after blood had been drawn for culture. These cultures grew Ps.
aeruginosa sensitive to cefotaxime. The patient responded well to therapy, and
cefotaxime was discontinued on day 46. The problem with diarrhoea had
worsened but, by day 46, results obtained by applying gas-liquid
chromatography to enrichment cultures ofthe patient's faeces suggested that the
infecting agent was C. difficile. Oral vancomycin was commenced at a dose of
500mg tid and, after initial improvement, the dose was reduced to 125mg qid,
finally being discontinued on day 57. By this time, the presence of C. difficile had
been confirmed and C. difficile toxin had been detected in the stool at a titre of
more than 1/800. The diarrhoea again worsened and by day 75 it became
necessary to re-start oral vancomycin 500mg tid for 5 days. By day 102, the
diarrhoea had recurred and was once again a serious problem. On this occasion
oral metronidazole was prescribed at a dose of 200mg qid. Following this, the
problem settled and by day 108 no toxin was detectable in faecal samples. On
day 1 14, metronidazole was discontinued and the patient has since remained
free from diarrhoea. Owing to the patient's physical frailty, sigmoidoscopy was
not performed during his illness. He was discharged on day 121, his urinary
problems having also settled.
DISCUSSION
C. difficile is an anaerobic spore-forming gram-positive organism with the ability
to manufacture a potent exotoxin.1 4 This bacterium is responsible for an acute
purulent infection of the colon, and the condition can manifest itself as a
pseudomembranous colitis or as diarrhoea and colitis without pseudomembrane
formation.3,4 The resulting clinical picture can be mild and self-limiting or
severely debilitating and prolonged, and on occasions the condition can present
as a life-threatening toxic megacolon, necessitating emergency colectomy.3 Both
organisms and free toxin are encountered in thestools ofaffected patients but not
in the faeces of patients with other established causes for diarrhoea and, in
addition, C. difficile is rarely carried by healthy adults.3 Consequently, if the toxin
is demonstrated in the stool, the diagnosis is considered established,3 and it has
been shown that clinical improvement is associated with the disappearance ofthe
toxin from faecal samples.4 Vancomycin is the established therapy of choice, and
metronidazole and bacitracin are also recognised as effective drugs in this clinical
setting.3 4
Casesofcolitis(and, rarely, ofpseudomembranous colitis)havebeenencountered
in patients receiving certain cephalosporin antibiotics.5 Cefotaxime, a third
generation cephalosporin, was first isolated in 1978.12 There have been few
reports of C. difficile induced colitis occurring with this drug, and these cases
have been encountered in West Germany,6 France7 and the U.S.A.8-11 This is
the first instance of the complication occurring with cefotaxime in the United
Kingdom.
© The Ulster Medical Society, 1985.
8182 The Ulster Medical Journal
This case emphasises and reinforces the importance of maintaining a high index
of clinical suspicion during and following cefotaxime therapy in order to avoid the
patient reaching the fulminating stages of a potentially lethal but nevertheless
treatable complication.
We are grateful to Dr Angus J Dougall, Consultant Bacteriologist at Stobhill General Hospital, for his
advice in the preparation of this paper. We are also indebted to the technical staff of the Microbiology
Laboratories at Stobhill and Ruchill Hospitals in Glasgow for performing the bacteriological
investigations.
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